Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Texas: - The Don and Sybil Harrington Cancer Center — Amarillo, Texas
- Dell Seton Medical Center at The University of Texas — Austin, Texas
- University of Texas at Austin — Austin, Texas
- Saint Joseph Regional Cancer Center — Bryan, Texas
- UT MD Anderson - The Woodlands — Conroe, Texas
Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Sites in Texas: - Texas Oncology - West Texas — Abilene, Texas
- Texas Oncology - West Texas — Amarillo, Texas
- Texas Oncology - Gulf Coast — Beaumont, Texas
- Texas Oncology - Northeast Texas — Denison, Texas
- Texas Oncology - Northeast Texas — Denton, Texas
Phase 3 Recruiting Industry
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Sites in Texas: - Texas Oncology - DFW — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- US Oncology Investigational Product Center (IPC) — Irving, Texas
- US Oncology Investigational Products Center (IPC) — Irving, Texas
Phase 3 Recruiting Industry
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…
Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Sites in Texas: - Clinical Study Site — Dallas, Texas
- Clinical Study Site — Dallas, Texas
- Clinical Study Site — Fort Worth, Texas
- Clinical Study Site — Houston, Texas
- Clinical Study Site — Houston, Texas
Phase 3 Recruiting Network
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Sites in Texas: - UT MD Anderson Cancer Center — Houston, Texas
- Scott and White Memorial Hospital — Temple, Texas
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Sites in Texas: - Texas Oncology West Texas — Abilene, Texas
- Parkland Health and Hospital System — Dallas, Texas
- Texas Oncology DFW — Dallas, Texas
- UT Southwestern Medical Center — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Texas: - Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
- UT Southwestern Clinical Center at Richardson/Plano — Richardson, Texas
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in Texas: - Texas Oncology Dallas Fort Worth West (DFWW) - Arlington Cancer Center North — Arlington, Texas
- Texas Oncology, PA — Austin, Texas
- Baylor College of Medicine Medical Center — Houston, Texas
- Texas Oncology - San Antonio — San Antonio, Texas
Phase 3 Recruiting Industry
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to b…
Sponsor: Rapamycin Holdings Inc.
NCT ID: NCT06950385
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard…
Sponsor: AbbVie
NCT ID: NCT07525206
Sites in Texas: - Texas Oncology - Abilene - Antilley Road /ID# 280120 — Abilene, Texas
- The University of Texas MD Anderson Cancer Center /ID# 279865 — Houston, Texas
Phase 2, Phase 3 Recruiting Academic/Other
A randomized study of 131 patients. Patients with a clinical T2-3 N0-1 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 …
Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
NCT ID: NCT03051464
Sites in Texas: - UT Southwestern Medical Center — Dallas, Texas
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Texas: - UT Southwestern Medical Center — Dallas, Texas
- Local Institution - 2127 — Houston, Texas
- MD Anderson Cancer Center — Houston, Texas
- Local Institution - 2146 — Kingwood, Texas
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Texas: - Texas Oncology - Central/South Texas — Austin, Texas
- Mary Crowley Cancer Research — Dallas, Texas
- Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas
- University of Texas Southwestern — Dallas, Texas
- Texas Oncology - Northeast Texas — Flower Mound, Texas
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Texas: - Baylor College of Medicine — Houston, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- NEXT Oncology Dallas — Irving, Texas
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Texas: - New Experimental Therapeutics - NEXT Oncology — Austin, Texas
- Texas Oncology — Bedford, Texas
- UT Southwest Simmons Cancer Center — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- New Experimental Therapeutics of San Antonio - NEXT Oncology — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas
- South Texas Accelerated Research Therapeutics, LLC — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Texas: - The Methodist Hospital Research Institute — Houston, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Industry
This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newl…
Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in Texas: - Lumi Research — Kingwood, Texas
- Laguna Clinical Research Associates — Laredo, Texas
Phase 2 Recruiting Industry
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
Sponsor: Verastem, Inc.
NCT ID: NCT07659795
Sites in Texas: - START Dallas Fort Worth — Fort Worth, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…
Sponsor: AbbVie
NCT ID: NCT07023289
Sites in Texas: - Texas Oncology - Central/South Texas /ID# 275154 — Austin, Texas
- The Center For Cancer And Blood Disorders /ID# 278512 — Fort Worth, Texas
- Texas Oncology-Grapevine /ID# 275155 — Grapevine, Texas
- The University of Texas MD Anderson Cancer Center /ID# 273539 — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in Texas: - University of Texas at Austin — Austin, Texas
- Mary Crowley Cancer Research — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Next Oncology — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RA…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07397338
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
- NEXT Dallas — Irving, Texas
- NEXT Oncology — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Texas: - Texas Oncology - West Texas — Amarillo, Texas
- Texas Oncology, P.A. — Dallas, Texas
- Texas Oncology Gulf Coast — Pearland, Texas
Phase 1, Phase 2 Recruiting Industry
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07488676
Sites in Texas: - Next Oncology - Austin — Austin, Texas
- Next Oncology - Houston — Houston, Texas
- Next Oncology - Dallas — Irving, Texas
- START San Antonio (STSA) — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy. Part 1 in…
Sponsor: Pfizer
NCT ID: NCT04557449
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas
- The University of Texas, MD Anderson Cancer Center - West Houston — Houston, Texas